Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly Plays Up Biotech But Major Pipeline Developments Are Long-Term

Executive Summary

Eli Lilly's biotech strategy calls for the creation of a pipeline that will yield one new biotechnology-based drug launch each year beginning in 2011, the company announced

You may also be interested in...

Lilly Gets Ready To Compete With Its Late-Stage Diabetes Pipeline

The Indianapolis-based pharma highlighted the Phase III results from two of its most promising pipeline candidates at ADA. The company is preparing to have four new diabetes drugs on the market by 2016, including two basal insulins, a GLP-1 agonist and a SGLT-2 inhibitor.

Shareholder Activism As Public Venture Capital? In Some Cases, It’s Icahn’s Approach

We never meant to sell ImClone right away, and we don’t intend to flip Biogen Idec if we win the proxy fight, Icahn director says.

Lilly’s Legal Division Steers Firm Through Rough Seas Of Civil, Patent Cases

Set in a campus-like complex in downtown Indianapolis, Lilly projects a calm, unruffled atmosphere. A water fountain bubbles in front of the administrative building. Windows line the building's two-story lobby, filling the place with light. In front of the reception desk there is a display on the history of insulin, which Lilly first brought to market in 1923. And a museum with relics of the company's 133-year history stands behind it

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts